Track 4 - January 23 11.30 A.M.-12.00 P.M.
Integrating real-world evidence in all phases of development allows moving from discovery into viable companion diagnostics. However, it doesn’t stop with access; the quality and quantity of RWE data contributes far more complexity. This panel will discuss the promise and challenges in the accelerated time to market for fit-for-patient diagnostics using RWE data.
Session Chair Profile
Chief Business Officer, Companion Diagnostics, Agilent Technologies
Biography
Trevor Page is currently the chief business officer of Agilent's companion diagnostic (CDx) division where he leads the business development and alliance management team responsible for establishing and maintaining CDx development partnerships with pharma and biotech. Over the past 10 years, Trevor helped to vitalize and grow Dako's companion diagnostic program into the Agilent CDx division it is today (Dako is now a subsidiary of Agilent). During this tenure, Trevor formed specific business development and alliance management functions as well as innovated partnering models to help successfully navigate the complex, dynamic and evolving nature of CDx collaborations.
Speaker Profile
Ph.D., Vice President, Biomaker Sciences, Gilead Sciences
Biography
Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Previously, he was Executive Director, Medical Sciences at Amgen, Inc, where he established the company’s biomarker strategy and led the In Vitro Diagnostics Group from its inception. Prior to Amgen, Dr. Patterson was Vice President, Proteomics at Celera Genomics. Earlier in his career, he held research appointments at Amgen and at Cold Spring Harbor Laboratory, New York. Dr. Patterson received BSc and PhD degrees from The University of Queensland in Australia.
Speaker Profile
Ph.D., Head, Companion Diagnostics Center of Excellence, AbbVie
Biography
Mirella Lazarov is a biomarker and translational medicine leader with over 18 years of experience, specializing in the areas of oncology, immunology and inflammation, ophthalmology, IBD, respiratory diseases, renal disease, and fibrosis. Mirella is currently at AbbVie, where she established and heads the Companion Diagnostics Center of Excellence, which leads the co-development of Companion Diagnostics across Therapeutic Areas. Previously Mirella has worked at Avalanche BioTech, Gilead, Roche, and Genentech where she undertook roles with increasing responsibility and established new functional capabilities for the companies in the areas of Precision Medicine, Biomarkers and Companion Diagnostics, and Translational Sciences. She has extensive experience in successfully co-developing therapeutics with companion diagnostics such as Tarceva (erlotinib), Zelboraf (vemurafenib) and others.
Speaker Profile
Vice President, Commercial Marketing, Agilent Technologies
Biography
Lou is responsible for developing and strengthening Agilent’s clinical brand and for providing reimbursement expertise across the DGG divisions. Lou brings more than 30 years of commercial and scientific experience in life sciences and molecular diagnostics. Lou joined HP early in his career in US commercial marketing. He held global positions with Agilent in marketing and product management, was a leader in global program management, and led the commercial strategy and launch of Agilent’s array CGH business. Lou co-founded Vela Diagnostics in 2011 and has held leadership roles at Roche Diagnostics and NanoString.
